<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The rapid growth of molecular genetics and its attendant germline mutation discoveries has enabled identification of persons who are at an inordinately high <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk and, therefore, ideal candidates for prevention </plain></SENT>
<SENT sid="1" pm="."><plain>However, one must fully appreciate the extensive genotypic and phenotypic <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> that exists in <z:e sem="disease" ids="C1333600" disease_type="Neoplastic Process" abbrv="">hereditary cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Once the causative germline mutation has been identified in a patient, high-risk members of the family can be similarly tested and identified and provided highly targeted surveillance and management opportunities </plain></SENT>
<SENT sid="3" pm="."><plain>DNA testing can change the individual's presumed risk status and affect decision making by patients and their physicians regarding surveillance and management </plain></SENT>
<SENT sid="4" pm="."><plain>Our purpose is to describe familial/<z:e sem="disease" ids="C1333600" disease_type="Neoplastic Process" abbrv="">hereditary cancers</z:e> of the gastrointestinal tract, including familial <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, hereditary diffuse <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, <z:hpo ids='HP_0100723'>gastrointestinal stromal tumors</z:hpo>, <z:e sem="disease" ids="C0032580" disease_type="Neoplastic Process" abbrv="">familial adenomatous polyposis</z:e> and <z:hpo ids='HP_0100245'>desmoid tumors</z:hpo>, <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>, <z:e sem="disease" ids="C0153425" disease_type="Neoplastic Process" abbrv="">small bowel cancer</z:e>, and familial <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>We use our discussion of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> as a model for diagnostic and clinical translation strategies for <z:hpo ids='HP_0000001'>all</z:hpo> hereditary <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal tract cancers</z:e>, which clearly can then be extended to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> of <z:hpo ids='HP_0000001'>all</z:hpo> anatomic sites </plain></SENT>
<SENT sid="6" pm="?"><plain>Highly pertinent questions from the patient's perspective include the following: What kind of counseling will be provided to a patient with a <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> mutation, and should that counseling be mandatory </plain></SENT>
<SENT sid="7" pm="?"><plain>Does the proband have the responsibility to inform relatives about the familial mutation, even if the relatives do not want to know whether they carry it </plain></SENT>
<SENT sid="8" pm="?"><plain>Is the patient is responsible for notifying family members that a parent or sibling has <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="9" pm="?"><plain>Can notification be forced and, if so, under what circumstances </plain></SENT>
<SENT sid="10" pm="."><plain>These questions point out the need for criteria regarding which family members to inform and how to inform them </plain></SENT>
</text></document>